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Background: Few larger studies have evaluated the long-term outcome after a diagnosis of papillary urothelial
neoplasm of low malignant potential (PUNLMP), demonstrating a broad range of recurrence and progression rates.
Additionally, no study has addressed the outcome of PUNLMP exhibiting inverted growth. We evaluated the long
term clinical outcome of primary papillary urothelial neoplasm of low malignant potential (PUNLMP), including
PUNLMP with inverted growth in a large single center study.
Methods: We evaluated 189 primary PUNLMP (177 exophytic, 12 inverted), diagnosed from January 1, 2000 to
December 31, 2009, in a centralized uropathology practice. We excluded PUNLMP diagnosed after a previous or
with a concurrent urothelial neoplasm. Recurrence was defined as any subsequent urothelial neoplasm, regardless
of the grade. Progression was defined as any subsequent higher-grade or invasive urothelial neoplasm. Recurrence
and progression were established only if documented on a subsequent biopsy. Descriptive statistical analysis was
performed using Microsof Excel software package.
Results: The location of PUNLMP included bladder (187) and renal pelvis and ureter (1 each). After a median
follow-up of 61 months (range, 9–128 months), 20.1% patients developed a recurrence. Recurrence with PUNLMP
only was found in 9% of patients. Subsequent low-grade urothelial carcinoma was documented in 9.5% of patients.
Progression to high-grade urothelial carcinoma was found in 1.6% patients (1% with muscle invasion). No patients
with recurrent PUNLMP or subsequent low-grade carcinoma demonstrated invasion. All patients with PUNLMP
exhibiting an inverted growth had no recurrence or progression on follow-up.
Conclusion: In this study, primary PUNLMP recurred primarily either as PUNLMP or low grade urothelial
carcinoma. Primary PUNLMP rarely progressed to high grade or invasive carcinoma on long term follow-up. No
recurrence or progression was documented on follow-up for PUNLMP that demonstrated exclusively inverted
growth.
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The inclusion of papillary urothelial neoplasm of low
malignant potential (PUNLMP) in the World Health
Organization (WHO) 2004 Classification of Tumours of
the Urinary System and Male Genital Organs resulted in
its wide use in clinical practice[1]. There is however an
ongoing debate if it indeed represents a distinct entity
which has a very low risk of progression, or if it is indis-
tinguishable from low-grade urothelial carcinoma, and
what is the clinical significance and the biologic behaviour
of PUNLMP [2-4]. Previous studies have typically ad-
dressed this entity in series evaluating the WHO 2004
classification system including other diagnostic categories
[5-14]. However, only three studies included more than
100 patients with PUNLMP [5,8,13]. The majority of pre-
vious studies were smaller, varied in design, had a patient
follow-up of less than 5 years and demonstrated broad
range of recurrence and progression rates. Possible con-
founders, which make comparisons between studies diffi-
cult, also included: intra- and inter-observer variability,
differences in inclusion criteria, length of follow-up and
the definition of progression [15]. The lack of transparent
study design is another confounding factor, which further
influenced the variations in reported results.
The objective of this study was to examine the recur-
rence and progression rates after a diagnosis of primary
(de novo) PUNLMP in a large regional urology practice,
including a group of primary PUNLMP with endophytic
growth, which demonstrated exclusive endophytic growth
(‘inverted PUNLMP’). Inverted PUNLMP, a recently intro-
duced concept, to our knowledge, has not been previously
studied and has uncertain clinical significance and behav-
iour [16,17]. We deliberately excluded from the study any
PUNLMP occurring in association with either previous or
concurrent urothelial neoplasm (secondary PUNLMP).
Methods
Patient selection
The study was approved by the institutional Ethics Re-
view Board. We identified 196 patients with a diagnosisFigure 1 Papillary urothelial neoplasm of low malignant potential (PU
are lined by multilayered urothelium with minimal to absent cytologic atypof primary (de-novo) PUNLMP, without a history of any
previously documented or concurrent urothelial neo-
plasm. These were consecutive cases, diagnosed during
a 10-year-period (January 1, 2000 to December 31,
2009) and were diagnosed using consistent criteria, in
one institution with a centralized regional urology and
uropathology setting. PUNLMP arising in association
with a previous or concurrent urothelial neoplasm and
consult cases were not included in the study by design.
All cases were reviewed by at least two pathologists
and 7 cases were excluded (reclassified as low-grade
urothelial carcinoma), resulting a final cohort of 189
patients with primary PUNLMP.
Histopathologic criteria
The PUNLMP diagnosis was based on the WHO 2004
Classification of Tumours of the Urinary System and Male
Genital Organs [1]. PUNLMP was defined as a papillary
urothelial tumor, which resembles exophytic urothelial
papilloma, but shows increased cellular proliferation, ex-
ceeding the thickness of the normal urothelium. The pa-
pillae of PUNLMP are discrete and non-fused and are
lined by multilayered urothelium with minimal to absent
cytologic atypia, preserved cell polarity and show only rare
mitoses, located basally, as illustrated in Figure 1. Similar
neoplasms, which demonstrated inverted (endophytic)
growth and resembled inverted papilloma, were also in-
cluded in the study (labelled ‘inverted PUNLMP’). In con-
trast to inverted urothelial papilloma, inverted PUNLMP
focally showed expanded and rounded cords and nests,
which were composed of architecturally and cytologically
bland and uniform urothelium, and showed only rare mi-
toses as illustrated in Figure 2. These neoplasms also
lacked central streaming and peripheral palisading, typic-
ally seen in inverted papilloma, in the areas with different
morphology.
Follow-up and evaluation of recurrence
Documented recurrence and progression episodes were
based solely on the subsequent biopsy findings, typicallyNLMP). The papillae of PUNLMP are discrete and non-fused (a). They
ia and preserved cell polarity (b).
Figure 2 Inverted papillary urothelial neoplasm of low malignant potential (Inverted PUNLMP). Inverted PUNLMP demonstrates inverted
(endophytic) growth and resembles inverted papilloma, but in contrast, shows expanded and rounded cords and nests, composed of architecturally
and cytologically bland urothelial cells (a and b). Inverted PUNLMP also lacks central streaming and peripheral palisading, as typically seen in
inverted papilloma.
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sis. Recurrence was defined as any subsequent neoplastic
lesion, including PUNLMP, low-grade urothelial carcin-
oma (LGUC) and high-grade urothelial carcinoma
(HGUC). Progression was defined as any subsequent
higher-grade or invasive lesion, including urothelial car-
cinoma in-situ.
Follow-up was obtained by review of electronic medical
records. The patients with PUNLMP diagnosis typically
would have had a follow-up cystoscopy within 3–6 months
from the initial diagnosis. The frequency of the subsequent
follow-ups and eventual cystoscopies and biopsies would
be dependent on the findings at the first follow-up and
subsequent clinical symptoms. Descriptive statistical
analysis was performed using Microsof Excel software
package.
Results
Of 189 patients with primary PUNLMP, 187 were lo-
cated in the bladder and 2 were found in the renal pelvis
and the ureter (1 each). The data on patient demograph-
ics, gender and follow-up are shown in Table 1. Overall,
20.1% (38/189) patients were ≤50 years old and 79.9%
(151/189) were > than 50 years old. No cancer-related
deaths were documented after primary-PUNLMP in any
of the patients.
PUNLMP recurrrence and progression data are sum-






Patients, no. (%) 189 (100) 3
Age at diagnosis, y median/mean (Range) 66/64 (19–92) 7
Male: Female 1.7 : 1 2
Follow up, mo, median/mean (Range) 61/64 (9–128)demonstrated recurrence or progression with a subse-
quent urothelial neoplasm, including PUNLMP, LGUC
and HGUC (with or without invasion). Recurrent
PUNLMP without any grade or stage progression was
seen in 9% (17/189) of patients. Grade progression to
either LGUC or HGUC was found in 11.1% (21/189) of
patients. Grade progression only to LGUC was seen in
9.5% (18/189), while progression to HGUC was found
in 1.6% (3/189) of patients). Median time to recurrent
PUNLMP was 13 months (mean 20; range 7–78
months), while the time interval to subsequent LGUC
was 47 months (mean 42; range 5–87 months). In pa-
tients with recurrence or progression, 84% (32/38) were
older than 50 years. Overall recurrence or progression
was documented in 21.2% (32/151) patients older than
50 years. Of 6 of 38 (15.8%) patients younger than
50 years, 4 had a subsequent diagnosis of non-invasive
LGUC and 2 had recurrent PUNLMP; no progression
to HGUC or invasive carcinoma was documented in
any patient younger than 50. Invasive carcinoma was
not seen in any of the 17 patients with recurrent
PUNLMP or in any of the 18 patients with subsequent
diagnosis of LGUC.
In 1.6% (3/189) patients with primary PUNLMP, there
was progression to HGUC (all male; age at first diagnosis
69, 72, and 80 years). Two patients with HGUC had in-
vasive carcinoma, while one patient had only non-







grade or high grade UC
8 (20.1) 17 (9) 21 (11.1)
0/66 (44–88) 69/66 (41–83) 71/67 (45–88)
.2 : 1 1.8 : 1 2.5 : 1
Table 2 Recurrence and progression in patients with primary PUNLMP
Recur to PUNLMP
No. (%)
Progress to low grade UC
No. (%)
Progress to high grade UC
No. (%)
Patients with recurrence/progression (N = 38) 17 (45) 18 (47) 3 (8)
Patients with one recurrence 10 12 1
Patients with multiple recurrences (Range) 7 (2 – 6) 6 (2 – 7) 2 (2 – 4)
Median/mean months to recurrence or progression (Range) 13/20 (5 – 78) 47/42 (5 – 87) 31/32 (4 – 61)
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muscle invasive HGUC at 61 months. He underwent cyst-
ectomy at 65 months, showing no residual invasive HGUC.
One patient had multiple biopsies documenting progres-
sion to urothelial in-situ-carcinoma (first at 4 months after
initial diagnosis) and pT1 invasive HGUC (at 20 months),
prior to cystectomy (at 49 months) which showed muscle
invasive HGUC with regional positive nodes. One patient
progressed to non-invasive papillary HGUC, without any
previous recurrences, at 31 months after initial PUNLMP.
Inverted PUNLMP
Inverted PUNLMP was found in 12 patients, who had a
median age of 61 years (mean 58; range, 31 to 74 years)
and a male to female ratio of 1:1. None of the 12 primary
PUNLMP with inverted growth had a documented recur-
rence or progression on follow-up (median 24 months;
mean 32; range, 2 to 80 months).
Discussion
With 189 primary PUNLMP patients, the study reported
herein, represents the second largest PUNLMP seriesTable 3 Recurrence and progression after PUNLMP reported i




[5] 112 29.5 3.6 10.7
[6] 8 33.3 NA 0
[21] 20 25 25 0
[7] 68 32.4 NA 0
[8] 116 32.8 NA 2.6
[9] 19 47.4 NA NA
[22] 29 NA NA 6.9
[10] 53 60 30 42
[11] 45 62.2 NA NA
[14] 12 25 NA 8.3
[18] 27 51.9 51.9 0
[12] 85 47.1 47.1 0
[13] 212 17.9 NA 1.9
[15] 31 41.9 12.9 29.0
Current study 189 20.1 9 11.1
Range 8-212 16.7-62.2 3.6-51.9 0-42documented to date. The diagnosis of primary PUNLMP
and the recurrences and progressions in this study were
predominantly found in individuals older than 50 years,
with a male to female ratio of about 2:1. The progres-
sions to HGUC or invasive carcinoma were documented
only in male patients, older than 65 years, which sug-
gests that closer follow-up is particularly warranted in
these patients, after a primary PUNLMP diagnosis. No
patient with primary ‘inverted PUNLMP’demonstrated
recurrence or progression on follow-up in this study.
The recurrence and progression rates after PUNLMP
reported herein are in the lower end of the previously
reported rates, which are quite broad, and range from
16.7% to 62.2% (Table 3). We found a recurrence and
progression rate of 20.1%, which is closer to the rates of
17.9% [13], 29.5% [5] and 32.8% [8], documented in the
largest previous studies containing more than 100 pa-
tients (Table 3). The rate of recurrence to PUNLMP,
without any grade or stage progression, was 9% in this
study, again, in the lower end of previously reported
rates of 3.6% to 51.9% [5,10,12,15,18]. Recurrence with









3.6 3.6 3.6 2.7
NA NA 0 0
0 0 0 NA
NA NA NA 0
NA NA NA 0.9
NA NA NA NA
NA NA 6.9 NA
34 0 8 0
NA NA NA NA
8.3 0 0 NA
0 0 0 0.0
0 0 0 NA
NA NA NA 0
25.8 3.2 0 0
9.5 1.6 1.0 0
0-34 0-3.6 0-8 0-2.7
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and 1.6% progressing to HGUC (1% with invasive car-
cinoma). The previous studies have documented a great
variety of grade or stage progression after PUNLMP
diagnosis, ranging from 0% to 42%. More specifically,
progression to LGUC ranged from 0% to 34%, progres-
sion to HGUC ranged 0% to 3.6%, and progression with
invasive carcinoma ranged from 0% to 8%.
The reported variations of recurrence and progression
after PUNLMP are likely primarily owing to the inter-
observer variations (i.e. the diagnostic criteria used), the
different definitions of progression and the differences in
the design of previous studies. Inter-observer, and possibly,
intra-observer variations, represent a major confounding
variable, dependent on the diagnostic criteria used (or
their subjective interpretation), and the diagnostic expert-
ise, experience and consistency of the pathologist, which
are often related to the type of practice [19,20]. The differ-
ences in the definition of recurrence and progression may
also be a major source of variation between studies, as
noted by Lee et al. [15]. The specific definitions of pro-
gression and recurrence with and without grade progres-
sion were explicitly stated only in some studies
[5,10,14,15,21]. Some studies however considered progres-
sion only when there was progression to HGUC [6,11,18]
or when the progression resulted in in-situ-carcinoma, in-
vasive carcinoma or metastases [13,22].
Variations in study design further limit the compari-
sons between the previous PUNLMP cohorts. For
example, it was infrequently specified whether only
primary (de novo) PUNLMP cases were studied
[6,11,18,21] and if secondary and consult cases were
evaluated. The method of documenting recurrence or
progression also varied significantly among studies. For
example, some studies combined cases of recurrence or
progression confirmed by biopsy, with cases in which re-
currence or progression were identified only on cytology
or cystoscopy with fulguration [5,7,11,14,18]. Some stud-
ies reported use of adjuvant chemotherapy, in addition
to transurethral resection, either in small subsets of
PUNLMP patients, or in larger cohorts with urothelial
tumors that included PUNLMP patients [8,13,22]. The
length of follow-up varied significantly among previous
studies as well. Lastly, in some studies, it is unclear if
data were derived from a single center or if they were
pooled from multiple institutions, potentially introdu-
cing greater inter-observer variability and inconsistencies
in the follow-up protocols, even within individual studies
[7,12,13,18]. In contrast, current study was restricted
only to primary PUNLMP cases, and the recurrences
and progressions were based solely on tissue biopsy find-
ings, reported in a centralized regional uropathology setting,
maintaining a degree of diagnostic consistency and redu-
cing the possibilities that biopsies were misdiagnosed,not accounted for, or performed and read elsewhere. Im-
portantly, no mortality associated with PUNLMP was
observed in this study, in keeping with the great majority
of previous studies.
In the current practice, PUNLMP and LGUC have an
almost identical clinical management [23]. However,
LGUC has a 2 to 3 times higher risk of grade/stage pro-
gression (range, 4%-18%) [6,8,13,14,18,21,22,24,25] and
also carries a higher risk for cancer-specific death (up
to 5%) [6,8,13,18,24-26], which is exceptionally rarely
documented in PUNLMP. More specific and tailored
management of these two entities may emerge based
on studies with cleaner and more transparent design, as
well as additional molecular and genetic studies, which
will hopefully provide additional markers for more pre-
cise separation of urologic malignancies. Until these
novel clinical markers are fully validated and used in
routine practice, the diagnosis and classification of
noninvasive urothelial neoplasms will be based strictly
on histomorphologic evaluation [13,23].
In this study, we also included 12 PUNLMP cases with
inverted growth (‘inverted PUNLMP’). To our know-
ledge, no previous study has formally acknowledged this
architectural pattern, explicitly stated its inclusion in the
analysis, or compared its clinical behaviour to the widely
recognized, typical exophytic PUNLMP. This is primarily
owing to the fact that inverted PUNLMP is a new and
recently proposed diagnostic category within the spectrum
of urothelial neoplasms with inverted (endophytic) growth,
as a counterpart to the typical PUNLMP with exophytic
growth [16,17]. Montironi and colleagues in a recent
editorial also suggested the term ‘Inverted urothelial
neoplasm of low malignant potential (IUNLMP)’, when
a papillary component is lacking and only inverted
growth exists [27]. Epstein et al. mention the existence
of ‘inverted PUNLMP’, stating that it is not currently
included in the WHO classification of urothelial tumours
and that no explicit definition or nomenclature currently
exists for it [16]. In their opinion, if an endophytic urothe-
lial lesion has notably thickened urothelium without archi-
tectural and cytologic atypia, the term ‘inverted-PUNLMP’
is appropriate. According to McKenney and Amin,
inverted, endophytic PUNLMP patterns exist, but they are
rare [17]. Although the group of ‘inverted-PUNLMP’ in-
cluded in this study is relatively small, no patient with
inverted-PUNLMP showed recurrence or progression on
follow-up. However, more data are needed to clarify the
biologic behaviour and appropriate management of these
lesions.
Limitations of the study include its retrospective de-
sign and the possible inter-observer variability. We were
also unable to accurately determine the prevalence of
PUNLMP in our practice, but we would estimate it to be
less than 3% of all urothelial neoplasms.
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We found a recurrence rate of 20.1% after primary
PUNLMP, in evaluating the long-term outcome of
primary-PUNLMP, including PUNLMP with inverted
growth (‘inverted PUNLMP’), in a large, single-center
study. Recurrence with PUNLMP only was seen in 9% of
patients, progression to LGUC only was seen in 9.5%
and progression to HGUC was seen in 1.6% of patients.
Primary PUNLMP and the subsequent recurrences and
progressions were predominantly found in male patients
older than 50 years. The progression to HGUC or inva-
sive carcinoma was documented only in male patients,
older than 65 years, which suggests that close follow-up
is particularly warranted in this patient group, after a
diagnosis of primary PUNLMP. The patients with pri-
mary inverted PUNLMP had no documented recurrence
or progression on follow-up.
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